Poor Reliability of Common Measures of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation

Area of Science:

• Pediatric critical care medicine
• Hematology
• Cardiovascular surgery

Background:

• Anticoagulation management during pediatric extracorporeal membrane oxygenation (ECMO) lacks standardized guidelines.
• Institutions use various laboratory measures, including partial thromboplastin time (PTT), thromboelastography (TEG), and antifactor Xa (aXa), without consensus.
• This variability complicates effective anticoagulation strategies in critically ill children.

Purpose of the Study:

• To evaluate the consistency of correlations between TEG R-time, PTT, and aXa with bivalirudin and heparin dosing in pediatric ECMO.
• To determine if specific laboratory measures reliably predict anticoagulation status during ECMO.
• To inform the development of more consistent anticoagulation monitoring protocols.

Main Methods:

• A single-center retrospective review of pediatric ECMO cases from 2018 to 2020 was conducted.
• Data included serial simultaneous measurements of TEG R-time, PTT, and aXa alongside bivalirudin or heparin dosing over a 7-day ECMO course.
• Statistical analysis focused on the correlation between anticoagulant dosing and laboratory parameters.

Main Results:

• Over 1,500 laboratory values from 67 ECMO runs (32 bivalirudin, 35 heparin) were analyzed.
• A majority of patients showed no consistent correlation between anticoagulant dosing and individual laboratory parameters.
• Significant correlations were observed only between dosing and the aggregate of all laboratory tests, not individual measures.

Conclusions:

• Individual laboratory tests (PTT, TEG R-time, aXa) are unreliable for isolated monitoring of anticoagulation in pediatric ECMO.
• Anticoagulation management requires a multimodal approach, integrating various laboratory data with clinical judgment.
• Further research is needed to establish evidence-based guidelines for anticoagulation monitoring in pediatric ECMO.